Top

Published in:

01-08-2011

Recurrent pancreatic carcinoma and cholangiocarcinoma: ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT)

Authors: Katherine Cameron, Sivan Golan, William Simpson, Steven Peti, Sasan Roayaie, Daniel Labow, Lale Kostakoglu

Published in: Abdominal Radiology | Issue 4/2011

Abstract

Although the current literature is limited, available data suggest that ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) imaging improves the evaluation of patients with recurrent pancreatic carcinoma and cholangiocarcinoma. There is evidence that PET/CT is particularly useful in the setting of elevated tumor markers and negative or equivocal CT findings. This article reviews the nature of these carcinomas in the post-therapy setting and describes the strengths and limitations of PET/CT when used for monitoring recurrence.

Jemal A, Siegel R, Ward E, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225PubMedCrossRef

American Gastroenterological Association medical position statement: epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 117:1463–1484 (1999)

West J, Wood H, Logan RF, Quinn M, Aithal GP (2006) Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971–2001. Br J Cancer 94(11):1751–1758PubMedCrossRef

Khan SA, Taylor-Robinson SD, Toledano MB, Elliott Beck A, Thomas HC P (2002) Changing international trends in mortality rates for liver, biliary and pancreatic tumors. J Hepatol 37(6):806–813PubMedCrossRef

Patel T (2002) Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 3(2):10CrossRef

Nehls O, Gregor M, Klump B (2004) Serum and bile markers for cholangiocarcinoma. Semin Liver Dis 24(2):139–154PubMedCrossRef

National Comprehensive Cancer Network (2008) Clinical practice guidelines in oncology, Hepatobiliary cancers. Version 2

Huang QJ, Xu Q, Wang XN, et al. (2002) Spiral multi-phase CT in evaluating resectability of pancreatic carcinoma. Hepatobiliary Pancreat Dis Int 1(4):614–619PubMed

Tamm EP, Loyer EM, Faria S, et al. (2006) Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy. Abdom Imaging 31(5):568–574

10.

Diehl SJ, Lehmann KJ, Sadick M, et al. (1998) Pancreatic cancer: value of dual-phase helical CT in assessing resectability. Radiology 206:373–378PubMed

11.

McCarthy MJ, Evans J, Sagar G, et al. (1998) Prediction of resectability of pancreatic malignancy by computed tomography. Br J Surg 85:320–325PubMedCrossRef

12.

Ohtani T, Shirai Y, Tsukada K, et al. (1993) Carcinoma of the gallbladder: CT evaluation of lymphatic spread. Radiology 189:875–880PubMed

13.

Ward EM, Stephens DH, Sheedy PF (1983) Computed tomographic characteristics of pancreatic carcinoma: an analysis of 100 cases. Radiographics 3:547–565.

14.

Solomon R (2009) Contrast-induced acute kidney injury (CIAKI). Radiol Clin North Am 47(5):783–788PubMedCrossRef

15.

Sperti C, Pasquali C, Bissoli S, et al. (2010) Tumor relapse after pancreatic cancer resection is detected earlier by 18-FDG PET than by CT. J Gastrointest Surg 14(1):131–140PubMedCrossRef

16.

Casneuf V, Delrue L, Kelles A, et al. (2007) Is combined 18F-flurodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions? Acta Gastroenterol Belg 70(4):331–338PubMed

17.

Ruf J, Lopez Hanninen E, Oettle H, et al. (2005) Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI. Pancreatology 5(2–3):266–272PubMedCrossRef

18.

Rose DM, Delbeke D, Beauchamp RD, et al. (1998) 18-Fluorodeoxyglucose-positron emission tomography (18FDG-PET) in the management of patients with suspected pancreatic cancer. Ann Surg 229:729–738CrossRef

19.

Franke C, Klapdor R, Meyerhoff K, Schauman M (1999) 18-F Positron emission tomography of the pancreas: diagnostic benefit in the follow-up of pancreatic carcinoma. Anticancer Res 19:2437–2442PubMed

20.

Jadvar H, Fischman AJ (2001) Evaluation of pancreatic carcinoma with FDG PET. Abdom Imaging 26(3):254–259PubMedCrossRef

21.

Kim J, Quon A, Humke E, Ford JM, Koong AC (2009) Detection of solitary humeral metastasis from pancreatic adenocarcinoma with F-18 FDG PET/CT. Clin Nucl Med 34(5):312–313PubMedCrossRef

22.

Corvera CU, Blumgart LH, Akhurst T, et al. (2008) ¹⁸F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg 206:57–65PubMedCrossRef

23.

Jadvar H, Henderson RW, Conti PS (2007) (18F) fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma. J Comput Assist Tomogr 31:223–228PubMedCrossRef

24.

Peters PE, Beyer K (1985) Normal lymph node cross-sections in different anatomic regions and their significance for computed tomographic diagnosis. Radiologe 25:193–198PubMed

25.

Dorfman RE, Alpern MB, Gross BH, Sandler MA (1991) Upper abdominal lymph nodes: criteria for normal size determined with CT. Radiology 180:319–322PubMed

26.

Lucey BC, Stuhlfaut JW, Soto JA (2005) Mesenteric lymph nodes: detection and significance on MDCT. Am J Roentgenol 184:41–44

27.

Pansky B (1990) Anatomy of the pancreas. Emphasis on blood supply and lymphatic drainage. Int J Pancreatol. 7(1–3):101–108

28.

Donatini B, Hidden G (1992) Routes of lymphatic drainage from the pancreas: a suggested segmentation. Surg Radiol Anat 14(1):35–42PubMedCrossRef

29.

Weber SM, Jarnagin WR, Klimstra D, et al. (2001) Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg 193(4):384–391PubMedCrossRef

30.

Yamamoto M, Takasaki K, Otsubo T, Katsuragawa H, Katagiri S (2001) Recurrence after surgical resection of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 8(2):154–157PubMedCrossRef

31.

Castaing D (2008) Surgical anatomy of the biliary tract. HPB 10:72–76PubMedCrossRef

32.

Diederichs CG, Staib L, Vogel J, et al. (2000) Values, limitations of ¹⁸F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas 20:109PubMedCrossRef

33.

Shreve PD (1998) Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med 25:259–264PubMedCrossRef

34.

Diederichs CG, Staib L, Glasbrenner B, et al. (1999) F-18 Fluorodeoxyglucose (FDG) and C-reactive protein (CRP). Clin Pos Imaging 2:131–136CrossRef

35.

Fritscher-Ravens A, Bohuslavizki KH, Broering DC, et al. (2001) FDG PET in the diagnosis of hilar cholangiocarcinoma. Nucl Med Commun 22:1277–1285PubMedCrossRef

36.

Kim YJ, Yun M, Lee WJ, Kim KS, Lee JD (2003) Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging 30(11):1467–1472PubMedCrossRef

37.

Anderson CD, Rice MH, Pinson CW, et al. (2004) Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. Gastrointest Surg 8(1):90–97CrossRef

38.

Li TR, Tian JH, Wang H, Chen ZQ, Zhao CL F (2009) Pitfalls in positron emission tomography/computed tomography imaging: causes and their classifications. Chin Med Sci J 24(1):12–19PubMedCrossRef

39.

Zimny M, Bares R, Fass J, et al. (1997) Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 24:678–682PubMed

40.

Kostakoglu L, Hardoff R, Mirtcheva R, Goldsmith SJ (2004) PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. Radiographics 24(5):1411–1431PubMedCrossRef

Title: Recurrent pancreatic carcinoma and cholangiocarcinoma: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT)
Authors: Katherine Cameron
Sivan Golan
William Simpson
Steven Peti
Sasan Roayaie
Daniel Labow
Lale Kostakoglu
Publication date: 01-08-2011
Publisher: Springer-Verlag
Published in: Abdominal Radiology / Issue 4/2011
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-011-9729-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Recurrent pancreatic carcinoma and cholangiocarcinoma: ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT)

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2011

Intraductal papillary mucininous neoplasm of the bile ducts: multimodality assessment with pathologic correlation

Hepatic epithelioid hemangioendothelioma: findings at CT and MRI including preliminary observations at diffusion-weighted echo-planar imaging

Differentiating focal eosinophilic liver disease from hepatic metastases using unenhanced and gadoxetic acid-enhanced MRI

Internal hernias after abdominal surgeries: MDCT features

Diagnosis of Budd–Chiari syndrome: three-dimensional dynamic contrast enhanced magnetic resonance angiography

Clinical usefulness of diffusion-weighted MR imaging for detection of pancreatic cancer: comparison with enhanced multidetector-row CT

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page